Correlation between Immune Microenvironment Features and EGFR Mutation Status 
in Lung Adenocarcinoma

• Published in: Zhongguo fei ai za zhi Vol. 26; no. 3; pp. 204 - 216
• Main Authors: Zhu, Hongyu, Chen, Peng, Dong, Guozhang, Meng, Fanchen, Xia, Zhijun, You, Jing, Kong, Xiangru, Wu, Jintao, Yuan, Fangwei, Yu, Xinyu, Sun, Qinhong, Ji, Jinfu, Wang, Siwei, Liu, Tongyan, Xu, Lin
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association; Chinese Antituberculosis Association 20.03.2023
• Subjects: Adenocarcinoma of Lung - pathology; B7-H1 Antigen - genetics; egfr mutation; ErbB Receptors - metabolism; Humans; immune microenvironment; immunotherapy; lung neoplasms; Lung Neoplasms - pathology; Mutation; Prognosis; tumor heterogeneity; Tumor Microenvironment - genetics; EGFR mutation; Immune microenvironment; Tumor heterogeneity; Immunotherapy; Lung neoplasms
• ISSN: 1999-6187; 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2023.101.07

The morbidity and mortality rates of lung cancer remain high worldwide, and lung adenocarcinoma is one of the most important tissue subtypes of lung cancer. Epidermal growth factor receptor (EGFR) mutation is an important driver gene mutation for lung adenocarcinoma. In recent years, immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, have achieved remarkable efficacy in some lung cancer patients. Patients with EGFR mutations enjoyed limited benefits from immunotherapy according to recent studies. This study aimed to explore the relationship between EGFR mutation status and the spatial distribution as well as infiltration number of various immune cells in patients with EGFR mutant lung adenocarcinoma. This study included 62 lung adenocarcinoma patients who underwent surgery. Through multi-point sampling of surgically removed tumor tissues in different areas, 223 tumor tissue samples were finally obtained. We aquired EGFR mutations